Literature DB >> 2110441

Serum IgA antibodies against Pseudomonas aeruginosa in cystic fibrosis.

M M Brett1, A T Ghoneim, J M Littlewood.   

Abstract

Serum IgA antibodies to Pseudomonas aeruginosa cell surface antigens were estimated by ELISA. Titres in patients with and without cystic fibrosis and with no pseudomonal infection were low (less than 105 to less than 261). Titres in patients with cystic fibrosis who were chronically infected with P aeruginosa were very high (1200-163,000), and patients who grew the organism intermittently had intermediate titres. Longitudinal studies suggested increasing tissue invasion or involvement of the lower respiratory tract, or both, with increasing time of infection and identified patients with a good prognosis after the onset of pseudomonal infection. Detection of an increased serum IgA titre can give an earlier indication than measurement of the serum IgG titre of the presence of P aeruginosa in the respiratory tract in a proportion of patients. IgA measurement seems to be better than IgG measurement at predicting the reappearance of P aeruginosa after apparent eradication of early infection. These results suggest that this assay may be a valuable additional indicator of the presence of P aeruginosa at the beginning of infection, and of the reappearance of the organism after treatment in the early stages of infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2110441      PMCID: PMC1792272          DOI: 10.1136/adc.65.3.259

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  12 in total

1.  The systematic evaluation of the chest radiograph in cystic fibrosis.

Authors:  A R Chrispin; A P Norman
Journal:  Pediatr Radiol       Date:  1974

2.  Bacterial flora of respiratory tract in patients with cystic fibrosis, 1950-71.

Authors:  M B Mearns; G H Hunt; R Rushworth
Journal:  Arch Dis Child       Date:  1972-12       Impact factor: 3.791

3.  An ELISA to detect antipseudomonal IgA antibodies in sera of patients with cystic fibrosis.

Authors:  M M Brett; A T Ghoneim; J M Littlewood
Journal:  J Clin Pathol       Date:  1988-10       Impact factor: 3.411

Review 4.  Expression of immune mechanisms in the lung.

Authors:  H B Kaltreider
Journal:  Am Rev Respir Dis       Date:  1976-03

5.  Monoclonal antibodies against Pseudomonas aeruginosa outer membrane antigens: isolation and characterization.

Authors:  R E Hancock; A A Wieczorek; L M Mutharia; K Poole
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

6.  Some aspects of immunity in patients with cystic fibrosis.

Authors:  J C Wallwork; P Brenchley; J McCarthy; J D Allan; D Moss; A M Ward; A Holzel; R F Williams; H McFarlane
Journal:  Clin Exp Immunol       Date:  1974-11       Impact factor: 4.330

7.  Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by enzyme-linked immunosorbent assay.

Authors:  S S Pedersen; F Espersen; N Høiby
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 5.948

8.  IgA and IgG antibodies against surface antigens of Pseudomonas aeruginosa in sputum and serum from patients with cystic fibrosis.

Authors:  P O Schiøtz; N Høiby; H Permin; A Wiik
Journal:  Acta Pathol Microbiol Scand C       Date:  1979-06

9.  Serum IgG antibodies in patients with cystic fibrosis with early Pseudomonas aeruginosa infection.

Authors:  M M Brett; A T Ghoneim; J M Littlewood
Journal:  Arch Dis Child       Date:  1987-04       Impact factor: 3.791

10.  Prediction and diagnosis of early Pseudomonas aeruginosa infection in cystic fibrosis: a follow-up study.

Authors:  M M Brett; A T Ghoneim; J M Littlewood
Journal:  J Clin Microbiol       Date:  1988-08       Impact factor: 5.948

View more
  9 in total

Review 1.  Microbiology of cystic fibrosis lung infections: themes and issues.

Authors:  J R Govan; J W Nelson
Journal:  J R Soc Med       Date:  1993       Impact factor: 5.344

2.  Interference of immunoglobulin G (IgG) antibodies in IgA antibody determinations of Chlamydia pneumoniae by microimmunofluorescence test.

Authors:  T Jauhiainen; T Tuomi; M Leinonen; J D Kark; P Saikku
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

3.  IgG antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  S M Cordon; J S Elborn; R J Rayner; E J Hiller; D J Shale
Journal:  Arch Dis Child       Date:  1992-06       Impact factor: 3.791

4.  Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis.

Authors:  M Kappler; A Kraxner; D Reinhardt; B Ganster; M Griese; T Lang
Journal:  Thorax       Date:  2006-01-31       Impact factor: 9.139

5.  Specific decrease of anti-pseudomonal IgA after anti-pseudomonal therapy in cystic fibrosis.

Authors:  K de Boeck; E Eggermont; M Smet; P van Reempts; H P van Bever; W J Stevens
Journal:  Eur J Pediatr       Date:  1995-02       Impact factor: 3.183

6.  Development of a PCR probe test for identifying Pseudomonas aeruginosa and Pseudomonas (Burkholderia) cepacia.

Authors:  E M O'Callaghan; M S Tanner; G J Boulnois
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

7.  Translocated LPS might cause endotoxin tolerance in circulating monocytes of cystic fibrosis patients.

Authors:  Rosa del Campo; Eriel Martínez; Carlos del Fresno; Raquel Alenda; Vanesa Gómez-Piña; Irene Fernández-Ruíz; María Siliceo; Teresa Jurado; Victor Toledano; Francisco Arnalich; Francisco García-Río; Eduardo López-Collazo
Journal:  PLoS One       Date:  2011-12-28       Impact factor: 3.240

Review 8.  IgY antibodies for the immunoprophylaxis and therapy of respiratory infections.

Authors:  Aymn Talat Abbas; Sherif Aly El-Kafrawy; Sayed Sartaj Sohrab; Esam Ibraheem Ahmed Azhar
Journal:  Hum Vaccin Immunother       Date:  2018-09-19       Impact factor: 3.452

9.  Lung immunoglobulin A immunity dysregulation in cystic fibrosis.

Authors:  Amandine M Collin; Marylène Lecocq; Sabrina Noel; Bruno Detry; François M Carlier; Frank Aboubakar Nana; Caroline Bouzin; Teresinha Leal; Marjorie Vermeersch; Virginia De Rose; Lucile Regard; Clémence Martin; Pierre-Régis Burgel; Delphine Hoton; Stijn Verleden; Antoine Froidure; Charles Pilette; Sophie Gohy
Journal:  EBioMedicine       Date:  2020-09-11       Impact factor: 8.143

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.